Summaries of publicly reported investigational studies of retatrutide (LY3437943). Educational reference only — retatrutide remains investigational and is not approved for human use in most jurisdictions.
Expanded investigational programmes are assessing outcomes across larger cohorts. Retatrutide remains investigational and is not approved for human use in most jurisdictions.
Mid-stage investigational trials explored a range of retatrutide doses and metabolic endpoints in adults with obesity, with results reported in the peer-reviewed literature.
Initial investigational studies characterised the pharmacokinetics and tolerability of retatrutide (LY3437943), establishing the groundwork for later dose-ranging research.
These summaries describe publicly reported research for educational purposes. They are not therapeutic claims and do not constitute medical advice. Products supplied by OnlineRetatrutide are strictly for in-vitro laboratory research.